Synairgen Share Discussion Threads

[nobbygnome] 12/4/2020 19:44

Let's get real. The first patient was dosed two weeks ago tomorrow. I would guess they have recruited about 25-30 patients so far but that will go up sharply now more clinical trial sites are coming on stream. Before they unblind the trial once it has finished they need to make sure all the data is entered correctly and clean up the database and once unblinded it will take 2 or 3 days to do the stats various ways, validate the results and formulate the story of the results.

So I stand by the end of May and will be pleasantly surprised if it's a week earlier.

[makendon] 12/4/2020 19:41

>>Tpi,

You're obviously having a great day! You have got to be the funniest Italian on here 😉

[time to share] 12/4/2020 18:51

"" Patients who are in hospital or non-hospitalised but high risk groups (e.g. elderly or diabetics) will be invited to take part in the trial. They would receive either SNG001 or placebo once daily for 14 days""

The approved date was 17/03/2020 for a 14 day trial.
Anyone know when the trial actually started.

[jrlomax] 12/4/2020 18:03

Just watched an interview with bill gates, he is going to support the 10 best treatments for covid 19. I hope we are one of them. He made a very interesting point about a vaccine in that the person getting it needs to have an immune system able to cope , as the vaccine triggers an immune response. Do treatments to boost the immune system are just as important.

[nobbygnome] 12/4/2020 16:16

>> tpi

Delirium! Have you been on the Prosecco again....

[bobaxe1] 12/4/2020 15:54

Demand grows

[bobaxe1] 12/4/2020 15:54

Access to SNG001 to treat individuals outside clinical trialsOn the 18th March Synairgen announced its plans to initiate a pilot clinical trial of SNG001 in COVID-19 patients. The trial will provide data on the efficacy of inhaled interferon beta in the treatment of ambulatory and hospitalised patients infected with SARS-CoV-2. Since the announcement, we have received a number of requests for SNG001 supplies to treat individuals outside the trial. As SNG001 is an experimental drug, untested as to safety and efficacy in this patient group, we regret that we are unable to fulfil any such request at this time. Synairgen's team is working very hard to establish these measures in a well-controlled environment as quickly as possible.

[the patient investor] 12/4/2020 15:16

"83p on Tuesday at 13:47: DREAM, DELIRIUM OR REALITY"


discASS

[blueblood] 12/4/2020 15:08

Put into perspective the cost of 1 night stay in intensive care is c£2k in UK. A treatment that stops escalating need to this level is huge potential cost saver for NHS

[pdt] 12/4/2020 14:58

Thanks for posting the article above

"Potent Antiviral Activities of Type I Interferons to SARS-CoV-2 Infection"

This was research by Texas Uni. A couple of days ago another article by Paris Uni shared the same opinion.

The former is also being tweeted about by Ali Mortazavi (current chairman at E-therapeutics and ex-chairman of Silence Therapeutics). he said "Came across this. Made me sit up and take notice of $SNG more. Has a shot imo. And yes I am a loooong time shareholder"

[royalalbert] 12/4/2020 14:41

Thanks Timbo, also you nobby.

[peachie 74] 12/4/2020 14:29

Cheers Timbo. Reassuring post.

[nobbygnome] 12/4/2020 14:18

>> timbo

Quality input as usual!

[nobbygnome] 12/4/2020 14:16

>> likya

You are adding 2+2 and getting 5! The number of participants as listed in the trial protocol has been discussed before as it always said 400 patients from the start. It is not clear to me why this is but could reflect the total once the pilot with 100 patients is completed. Anyway don’t expect an RNS about it on Tuesday because it’s not new news!

[likya123] 12/4/2020 14:08

Looks like trial extended from 100 to 200 to 400 patients and now 20 sites!!

Nobby, perhaps a little email to Richard?

If true very very significant...news on Tuesday morning looks likely..

From lse board.........





Article says 400 patients??

“Synairgen
Synairgen are a UK research company running an RCT of Interferon B in Covid19 patients.?6? It is a A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFNß-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection (COVID-19)
Interferon Beta is a promising drug that modulates the immune response to viral infections. It’s been shown to have antiviral activity in MERS Co-V, but again it is unproven in humans and in Covid19. The trial will recruit 400 hospitalised patients with proven Covid19. The drug is delivered by nebuliser.“

From RNS 18th March....note ‘initially’

COVID-19 Clinical Trial

Synairgen's Phase II trial in COVID-19 patients (SG016) will be a double-blind, placebo-controlled trial. Initially, the pilot phase of the study will involve 100 COVID-19 patients, will take place across a number of NHS trusts and has been adopted by the NIHR Respiratory Translational Research Collaboration which is comprised of leading centres in respiratory medicine in the UK whose internationally recognised experts are working together to accelerate development and discovery for COVID-19. A successful outcome from the pilot phase will inform onwards progression of SNG001 in COVID-19 patients. The trial is expected to commence imminently. 

RNS 31st March, extended to 6 sites...

“Synairgen has initiated a further six trial sites which are expected to start dosing in the coming days.”

So do we now have 400 patients following the Southampton pilot? Obviously I don’t know the timing of decisions etc but if the article is true this is very promising.

[likya123] 12/4/2020 14:04

Looks like trial extended from 100 to 200 to 400 patients and now 20 sites!!

Nobby, perhaps a little email to Richard?

If true very very significant...news on Tuesday morning looks likely..

From lse board.........





Article says 400 patients??

“Synairgen
Synairgen are a UK research company running an RCT of Interferon B in Covid19 patients.?6? It is a A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFNß-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection (COVID-19)
Interferon Beta is a promising drug that modulates the immune response to viral infections. It’s been shown to have antiviral activity in MERS Co-V, but again it is unproven in humans and in Covid19. The trial will recruit 400 hospitalised patients with proven Covid19. The drug is delivered by nebuliser.“

From RNS 18th March....note ‘initially’

COVID-19 Clinical Trial

Synairgen's Phase II trial in COVID-19 patients (SG016) will be a double-blind, placebo-controlled trial. Initially, the pilot phase of the study will involve 100 COVID-19 patients, will take place across a number of NHS trusts and has been adopted by the NIHR Respiratory Translational Research Collaboration which is comprised of leading centres in respiratory medicine in the UK whose internationally recognised experts are working together to accelerate development and discovery for COVID-19. A successful outcome from the pilot phase will inform onwards progression of SNG001 in COVID-19 patients. The trial is expected to commence imminently. 

RNS 31st March, extended to 6 sites...

“Synairgen has initiated a further six trial sites which are expected to start dosing in the coming days.”

So do we now have 400 patients following the Southampton pilot? Obviously I don’t know the timing of decisions etc but if the article is true this is very promising.

[rafboy] 12/4/2020 12:12

I did wonder about inhalers. Good to see it could be of use to asthmatics in such devices.

[nobbygnome] 12/4/2020 12:10

>> royalalbert

Already done...

[nobbygnome] 12/4/2020 12:08

And of course the possibility of stock piling is a real factor too. Think back to when tamiflu was stockpiled by governments in case of a bad flu epidemic. The same could be done with SNG001 and the beauty of that is with a relatively short shelf life of say 18 months, those stockpiles have to be replaced on a regular basis.

[nobbygnome] 12/4/2020 12:06

>> 141

There is a real hope that ultimately this drug could be used as a prophylactic. In other words people in a high risk group might have an inhaler all the time and take it on the first sign of any symptoms.

And also worth adding that the virus reduces interferon production as part of its modus operandi. It s a way of evading the immune system.